(RTTNews) - CytomX Therapeutics, Inc. (CTMX) announced that the first patient has been dosed in the combination arm of its ongoing Phase 1 clinical trial, evaluating CX-801 in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results